China
Africa
Explore chapters and articles related to this topic
Klippel−Trenaunay Syndrome
Published in Dongyou Liu, Handbook of Tumor Syndromes, 2020
Sclerotherapy eliminates the pain and discomfort of varicose veins and prevents complications such as venous hemorrhage and ulceration, through injection of a solution directly into the varicose veins to make them collapse and disappear. A variant of sclerotherapy involves injection of a foaming agent mixed with a sclerosing agent under ultrasound guidance. After the foaming agent moves blood out of the vein, the sclerosing agent has better contact with the vein wall.
Surgical therapy of venous malformation combined with embolo-/sclerotherapy: How much and when?
Published in Byung-Boong Lee, Peter Gloviczki, Francine Blei, Jovan N. Markovic, Vascular Malformations, 2019
However, in our experience, many patients do not accept that numerous treatment sessions with sclerotherapy over many years would be required until dramatic symptom improvement occurs. We have seen young patients who have been treated with sclerotherapy (e.g., for more than 10 years) become discouraged and dissatisfied with treatment results, leading them to seek another treatment option and discovering for the first time that a surgical treatment is possible. It is worth emphasizing that traditionally the parents/guardians of patients with vascular malformation or the patients themselves are not sufficiently informed about treatment options (due to lack of expertise among medical providers). One of these patients was treated with surgical resection that provided (over 6 years follow-up) complete resolution of symptoms. After that, further individual sessions of sclerotherapy were required to maintain the achieved results, as recurrent venectasias were visible, and the patient wanted their removal.
Sclerotherapy Of Esophageal Varices
Published in John P. Papp, Endoscopie Control of Gastrointestinal Hemorrhage, 2019
Complications due to sclerotherapy occurred in 12% out of 909 patients (Table 8). Marked pleural effusions were detected by routine thorax X-ray 24 hours after sclerotherapy was done in 18 patients (2%). Painful and deep esophageal ulcers that did not perforate into the mediastinum were detected by water soluble contrast in 3.1%, while complete transesophageal necrosis (Figure 8) with mediastinitis and/or pyothorax made up another 2%. Esophageal stenosis resulted from sclerotherapy in 22 patients (2.4%) and could be easily dilated by means of the Eder-Puestow device (Key Med). Hemorrhage from gastric varices was also considered to be a complication of sclerotherapy and is, therefore, listed in this group accounting for 2.4%.
Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma
Published in Journal of Dermatological Treatment, 2022
Hagar Bessar, Abdalla Hassan Kandil, Noha Mohammed Nasr, Fathia Khattab
It is important to note that our result in favor of ICZ regarding the treatment period (only 2–3 weeks) and the drug dose (daily and total) which were both statistically significant. Because of the lack of another similar study comparing both treatment modalities, even the only reported research by Panditray et al. (20) had added sclerotherapy to treatment and fixed the duration by 8 weeks. We still encourage using of ICZ to shorten both treatment period and total drug dosage. Various research comparisons revealed that the ideal dosage for ICZ is 2–3 weeks and for propranolol is 6 months and was confirmed by good response in our study and also is supported by Ran et al. (5) whose daily dose of itraconazole was approximately 5 mg/kg per day (range, 20–50 mg/day) and the mean cumulative dose was approximately 1299 mg (range, 280–2379 mg), and also with the agreement of Aletaha et al. (4) his maintenance dose of propranolol was 1–2 mg/kg/day divided into two doses and also matched with Marqueling et al. (17) whose dose of propranolol was 2 mg/kg/day, while superior doses were used by Podiatry et al. (20) whose study compared between oral itraconazole and propranolol plus sclerotherapy as his patients were adult.
Recent developments on foaming mechanical and electronic techniques for the management of varicose veins
Published in Expert Review of Medical Devices, 2019
C. Davide Critello, Salvatore A. Pullano, Thomas J. Matula, Stefano De Franciscis, Raffaele Serra, Antonino S. Fiorillo
Foam sclerotherapy has become a valid alternative to other minimally invasive procedures being less invasive and cost-effective. Compared to laser treatments and other modalities, the cost-effectiveness of foam sclerotherapy is much more obvious in the medium term (6 months), since the recurrence rates are higher at 5 years [8]. The foam treatment can be performed in an outpatient setting such as a physician’s office. It is also less aggressive, less painful, and needs no anesthesia as compared to the other endovenous ablation treatments [9]. Sclerotherapy involves the injection of a chemical agent with the aim of inducing vein obliteration. This is the oldest among the minimally invasive procedures since first injection treatments date back in 1853. However, sclerotherapy was popularized by Fegan in the 1960s. The idea of injecting chemical agents in foam format has been around for more than 70 years [10]. Renewed interest has resulted from superior efficacy in comparison with liquid injections [11]. Other advantages have concerned a larger contact surface with the endothelial, less amount of sclerosing agent to be injected, intense and prolonged venous spasm, homogeneous filling of the venous lumen, echogenicity, low percentage of recanalization and less tissue damage during extravasation.
The efficacy of OK-432 sclerotherapy on thyroglossal duct cyst and the influence on a subsequent surgical procedure
Published in Acta Oto-Laryngologica, 2019
Tomoyasu Tachibana, Shin Kariya, Yorihisa Orita, Takuma Makino, Takenori Haruna, Yuko Matsuyama, Yasutoshi Komatsubara, Yuto Naoi, Michihiro Nakada, Yoji Wani, Soichiro Fushimi, Machiko Hotta, Katsuya Haruna, Tami Nagatani, Yasuharu Sato, Kazunori Nishizaki
Patient characteristics are summarized in Table 1. The patients comprised 11 males and 9 females, with a mean age of 44.1 years old (range 15–75). The long diameter of TDC was <20 mm in 5 patients and ≥20 mm in 15 patients. The inner pattern of TDC showed multilocular cyst in 11 patients (55.5%) and unilocular cyst in 9 patients (45.5%). TDC was located at the suprahyoid region in 1 patient and at the infrahyoid region in 19. Of the 19 patients except for a patient with unknown symptoms, 12 patients complained of pain following sclerotherapy. Of these 12 patients, 9 patients required no medication for pain control, and the other 2 were treated with a non-steroidal anti-inflammatory drug (loxoprofen sodium).